Generated by AI
Achieve Life Sciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for nicotine dependence. Its primary product is cytisinicline, an investigational therapy derived from the naturally occurring alkaloid cytisine. The compound is designed to interact with nicotinic acetylcholine receptors in the brain, helping reduce nicotine cravings and withdrawal symptoms for people seeking to stop smoking or vaping. The company’s activities span late-stage clinical development, regulatory preparation, and commercialization efforts across markets including the United States, Canada, and the United Kingdom. Achieve Life Sciences, Inc. operates within the pharmaceutical and smoking-cessation sectors, addressing a major public-health need associated with tobacco and nicotine use. Its focused product portfolio and emphasis on a single therapeutic area distinguish it from diversified drug manufacturers, while its work supports the development of prescription-based options for nicotine independence.
Website22722 29th Dr. SE
Bothell, WA, 98021
United States
The latest articles about ACHV.
SEATTLE and VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty ph...
Detailed price information for Achieve Life Sciences Inc (ACHV-Q) from The Globe and Mail including charting and trades.
Summary of Aug 14's posts. Generated by AI.
Summary of May 12's posts. Generated by AI.
Summary of Jul 21's posts. Generated by AI.
Investors talking about ACHV also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.